Verici Dx (VRCI) Share Price, News & Analysis

Company Overview

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners. The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Key Stats

• Today's Range: 3.04 to 3.38
• 50-Day Range: 2.48 to 5.83
• 52-Week Range: 2.27 to 13
• Volume: 78,549 shs
• Average Volume: 638,874 shs
• Market Capitalization: £9.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VRCI Stock Analysis - Frequently Asked Questions

How have VRCI shares performed this year?

Verici Dx's stock was trading at GBX 3.70 on January 1st, 2025. Since then, VRCI stock has decreased by 17.9% and is now trading at GBX 3.04.
View the best growth stocks for 2025 here.

How do I buy shares of Verici Dx?

Shares of VRCI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Verici Dx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verici Dx investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:VRCI
• CUSIP: N/A
• CIK: N/A
• Web: www.vericidx.com
• Phone: 44 207 9338780
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-6,556,267.52
• Net Margins: -110.99%
• Pretax Margin: N/A
• Return on Equity: -71.67%
• Return on Assets: -26.14%

Debt

• Debt-to-Equity Ratio: 4.64
• Current Ratio: 4.54
• Quick Ratio: 8.49

Sales & Book Value

• Annual Sales: £5.91 million
• Price / Sales: 1.56
• Cash Flow: GBX 2.31 per share
• Price / Cash Flow: 1.31
• Book Value: GBX 4.43 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 303,513,234
• Free Float: N/A
• Market Cap: £9.22 million
• Optionable: Not Optionable
• Beta: 1.59